Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Articles
FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs, October 4, 2022, Through August 4, 2023
Read More
FDA Approvals
FDA Accelerated the Approval of Talvey, First Bispecific GPRC5D-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Read More
FDA Approvals
FDA Approved Izervay for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
Read More
FDA Approvals
FDA Approved Xdemvy, First Treatment for Demodex Blepharitis
Read More
FDA Approvals
FDA Accelerated the Approval of Veopoz, First Drug for the Treatment of Patients With CHAPLE Disease
Read More
FDA Approvals
FDA Accelerated the Approval of Sohonos, First Drug for the Treatment of Fibrodysplasia Ossificans Progressiva
Read More
FDA Approvals
FDA Accelerated the Approval of Akeega, First and Only Dual-Action Tablet for Metastatic Prostate Cancer With BRCA Mutation
Read More
FDA Approvals
FDA Granted Accelerated Approval to Elrexfio, a Bispecific BCMA-Directed CD3 T-Cell Engager, for Relapsed or Refractory MM
Read More
FDA Approvals
Hepzato Kit FDA Approved as a Liver-Directed Treatment for Uveal Melanoma With Hepatic Metastases
Read More
FDA Approvals
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Read More
2
3
4
5
6
7
8
Page 5 of 246
Results 41 - 50 of 2458